ASCO: Jazz shares 'unprecedented' HER2 biliary tract cancer data ahead of FDA decision

[cafead]

via As zanidatamab awaits an FDA approval decision, Jazz Pharmaceuticals is sharing long-term phase 2b data in advanced biliary tract cancer (BTC) for the HER2-targeted bispecific antibody.

article source